The New Frontier of Immuno-Oncology
Pionyr Immunotherapeutics is a clinical stage company developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity.
About Pionyr Immunotherapeutics
The company’s approach, Myeloid Tuning™, is designed to enhance the immune system’s anti-tumor response by altering, or “tuning”, the myeloid infiltrate of the tumor microenvironment with high specificity and for very specific purposes.
Pionyr’s Myeloid TuningTM technology builds on the discovery that altering the tumor microenvironment to favor immune-activating cells over immune-suppressing cells enhances the body’s ability to combat cancer.
Pionyr has a deep and diversified pipeline of myeloid targeting monoclonal antibody therapeutics. The PY314 and PY159 programs, targeting TREM2 and TREM1 respectively, are currently in Phase 1 clinical trials. Pionyr has also completed IND-enabling studies for a third program, PY265, which targets MARCO.
Become a Pionyr
Pionyr Immunotherapeutics is currently seeking individuals with myeloid biology, immunology, assay development, in vivo pharmacology, DMPK, or translational science expertise to help advance our lead programs into clinical testing.
June 2-6, 2023
ASCO 2023, Chicago, IL & Virtual
Pionyr Poster Presentation
July 18-20, 2023
Tumor Myeloid-Directed Therapies, Boston, MA
May 25, 2023
Pionyr Immunotherapeutics’ Phase 1a Study of TREM1-targeting Antibody PY159 for the Treatment of Solid Tumors Featured at ASCO 2023
March 23, 2023
Pionyr Immunotherapeutics and Gilead Change Exclusive Option Agreement
November 7, 2022
Pionyr Immunotherapeutics’ MARCO-targeting Antibody Program, PY265, for Treatment of Solid Tumors Featured at SITC 2022
September 20, 2022
Pionyr Immunotherapeutics Doses First Patient in Phase 1b Expansion Study of PY159
May 26, 2022
Pionyr Immunotherapeutics’ Phase 1a Study of TREM2-targeting Antibody PY314 for the Treatment of Solid Tumors Featured at ASCO 2022
May 3, 2022
Pionyr Immunotherapeutics Adds Three Leading Oncology Researchers and Drug Developers to Scientific Advisory Board
March 22, 2022
Pionyr Immunotherapeutics Presents on Third Myeloid-Directed Therapeutic Program at Keystone Symposium
March 8, 2022
Pionyr Immunotherapeutics Doses First Patient in Phase 1b Expansion Study of PY314
Pionyr Immunotherapeutics Inc.
2 Tower Pl, Suite 800
South San Francisco, CA 94080